Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts.
Alzheimer's disease (AD) is the most common cause of dementia. The mechanism of disease development and progression is not well understood, but increasing evidence suggests multifactorial etiology, with a number of genetic, environmental, and aging-related factors. There is a growing body of evidence that metabolic defects may contribute to this complex disease. To interrogate the relationship between system level metabolites and disease susceptibility and progression, the AD Metabolomics Consortium (ADMC) in partnership with AD Neuroimaging Initiative (ADNI) is creating a comprehensive biochemical database for patients in the ADNI1 cohort. We used the Biocrates Bile Acids platform to evaluate the association of metabolic levels with disease risk and progression. We detail the quantitative metabolomics data generated on the baseline samples from ADNI1 and ADNIGO/2 (370 cognitively normal, 887 mild cognitive impairment, and 305 AD). Similar to our previous reports on ADNI1, we present the tools for data quality control and initial analysis. This data descriptor represents the third in a series of comprehensive metabolomics datasets from the ADMC on the ADNI.
St John-Williams, L; Mahmoudiandehkordi, S; Arnold, M; Massaro, T; Blach, C; Kastenmüller, G; Louie, G; Kueider-Paisley, A; Han, X; Baillie, R; Motsinger-Reif, AA; Rotroff, D; Nho, K; Saykin, AJ; Risacher, SL; Koal, T; Moseley, MA; Tenenbaum, JD; Thompson, JW; Kaddurah-Daouk, R; Alzheimer’s Disease Neuroimaging Initiative, ; Alzheimer’s Disease Metabolomics Consortium,
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)